Albeit uncommon, interstitial lung disease (ILD) is potentially life-threatening, and patients treated with HER2-targeting ADCs should be carefully monitored, according to the previous experience with T-DM1 [70,71]. The gene discussed is ERBB2; the disease is interstitial lung disease.